Tracers / [177Lu]Lu-DOTA-CCK-66
[177Lu]Lu-DOTA-CCK-66
Also written as [Lu-177]Lu-DOTA-CCK-66
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated minigastrin/CCK-2 receptor-targeting peptide analog
- Target / mechanism
- Cholecystokinin-2 receptor (CCK-2R) PMID 42477299
- Clinical application
- Preclinical radioligand therapy of CCK-2R-expressing tumors (medullary thyroid carcinoma model) PMID 39392495
- Theranostic pair
- <a href="/tracers/ga68-dotacck66/">ga68-dotacck66</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >99% | ≥95% | DOTA-CCK-66 | 42477299 2026 EJNMMI Radiopharm Chem After radiolabeling at 90 °C for 15 min, 10 µL of 0.1 M sodium L-ascorbate (in PBS) was added. — 177Lu-Labeling afforded the reference compounds [177Lu]Lu-DOTA-PP-F11N ([177Lu]Lu-2) and [177Lu]Lu-DOTA-CCK-66 ([177Lu]Lu-4) in quantitative radiochemical yields (RCY > 99%) |
| Manual synthesis | — | none | >99% no | >95% | DOTA-CCK-66 | 39392495 2025 Eur J Nucl Med Mol Imaging Synthesis of the 177Lu-labeled peptide was performed at 95 °C for 5 min. — 177Lu-labeling was accomplished in an RCY > 99% (non-decay corrected) |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-CCK-66, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 39392495: 'DOTA-CCK-66'. Stage set/updated at stage 23 from PMID 39392495: 'Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy.'.